NASDAQ:TGTX
Tg Therapeutics, Inc.
Tg Therapeutics, Inc.'s revenue grew 87.3% in fiscal 2025 to $616.3M while operating margin rose to 20.0%, its highest in 10 years. Free cash flow was −$25.0M, −4.1% of revenue, and the diluted share count rose 0.7%.Summary generated from Tg Therapeutics, Inc.'s SEC filings. Latest annual report filed Feb 27, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$616.3M
Revenue growth+87.3%
Revenue, 5-yr CAGR+426.7%
Gross margin83.7%
Operating margin20.0%
Net margin72.6%
ROIC22.4%
Return on equity102.8%
Debt / equity0.38
Free cash flow−$25.0M
FCF margin−4.1%
Share count change+0.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 7 | 3 | 234 | 329 | 616 |
| Operating income | −345 | −218 | 21 | 42 | 123 |
| Net income | −348 | −224 | 13 | 23 | 447 |
| Free cash flow | −296 | −176 | −31 | −41 | −25 |
Recent filings
- 4Insider transaction report
Sep 14, 2026 - 4Insider transaction report
Aug 7, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 3, 2026 - 8-KResults of a shareholder vote
Jun 12, 2026 - 8-KOther events
Jun 3, 2026 - 8-KOther events
May 27, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 6, 2026